Company

Nucleome Therapeutics Limited

Nucleome Therapeutics uses 3D genome analysis to discover precision medicines.

About

Nucleome Therapeutics develops precision medicines for lymphocyte and autoimmune-related diseases using a 3D genome analysis platform and machine learning to identify disease-related genetic variations. The company was founded in 2019 in the UK by Danuta Jeziorska, Jim Hughes, and James Davies. In October 2022, it raised GBP 37.5 million in Series A funding from M Ventures, Johnson and Johnson Innovation, Pfizer Ventures Investments, British Patient Capital, and Oxford Science Enterprises.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in